nach oben

Erschienen in:

09.03.2017 | PHASE I STUDIES

A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel

verfasst von: Lillian M. Smyth, Kelsey R. Monson, Komal Jhaveri, Alexander Drilon, Bob T. Li, Wassim Abida, Gopa Iyer, John F. Gerecitano, Mrinal Gounder, James J. Harding, Martin H. Voss, Vicky Makker, Alan L. Ho, Pedram Razavi, Alexia Iasonos, Philip Bialer, Mario E. Lacouture, Jerrold B. Teitcher, Joseph P. Erinjeri, Nora Katabi, Matthew G. Fury, David M. Hyman

Erschienen in: Investigational New Drugs | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Summary

Purpose We previously reported the phase I dose escalation study of buparlisib, a pan-class 1A PI3K inhibitor, combined with platinum/taxane-based chemotherapy in patients with advanced solid tumors. The combination was well tolerated and promising preliminary efficacy was observed in PTEN deficient tumors. This phase I dose expansion study now evaluates buparlisib plus high dose carboplatin and paclitaxel in unselected patients with advanced solid tumors and buparlisib plus standard dose carboplatin and paclitaxel in patients with PTEN deficient tumors (ClinicalTrials.gov, NCT01297452). Methods There were two expansion cohorts: Cohort A received continuous buparlisib (100 mg/daily) orally plus high dose carboplatin AUC 6 and paclitaxel 200 mg/m2; Cohort B treated patients with PTEN deficient tumors only and they received the recommended phase II dose (RP2D) of continuous buparlisib (100 mg/daily) orally plus standard dose carboplatin AUC 5 and paclitaxel 175 mg/m2. Both cohorts received chemotherapy intravenously on day 1 of the 21-day cycle with pegfilgrastim support. Primary endpoint in Cohort A was to evaluate the safety and tolerability of chemotherapy dose intensification with buparlisib and in Cohort B was to describe preliminary efficacy of the combination among patients with tumors harboring a PTEN mutation or homozygous deletion. Results 14 subjects were enrolled, 7 in Cohort A and 7 in Cohort B. Dose reductions were required in 5 (71%) and 3 (43%) patients, in cohort A and B respectively. Grade 3 adverse events in Cohort A included lymphopenia (n = 5 [71%]), hyperglycemia (n = 2, [29%]), diarrhea (n = 2, [29%]) and rash (n = 2, [29%]) and in cohort B included lymphopenia (n = 5 [71%]), hyperglycemia (n = 4 [57%]) and neutropenia (n = 2 [29%]. The mean number of cycles on protocol was 6. The overall objective response rate was 14% (2 /14). No objective responses were observed in the PTEN deficient cohort. Four out of 6 patients with stable disease (SD) had SD or better for ≥6 cycles, 2 of which had PTEN deficient tumors. Conclusion The addition of buparlisib to high dose carboplatin and paclitaxel was not tolerable. The combination did not reveal significant clinical activity amongst a small and heterogenous group of PTEN deficient tumors,

Nur mit Berechtigung zugänglich

Engelman JA (2009) Targeting pi3k signalling in cancer: opportunities, challenges, and limitations. Nat Rev Cancer 9(8):550–562CrossRefPubMed

Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JKV et al (2004) High frequency of mutations of pik3ca gene in human cancers. Science 304:554CrossRefPubMed

Sansal I, Sellers WR (2004) The biology and clinical relevance of the pten tumor suppressor pathway. J Clin Oncol 22:2954–2963CrossRefPubMed

Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase-akt pathway in human cancer. Nat Rev Cancer 2(7):489–501CrossRefPubMed

Dillon LM, Miller TW (2014) Therapeutic targeting of cancers with loss of pten function. Curr Drug Targets 15(1):65–79CrossRefPubMedPubMedCentral

Planchon SM, Waite KA, Eng C (2008) The nuclear affairs of pten. J Cell Sci 121(Pt 3):249–253CrossRefPubMed

Yin Y, Shen WH (2008) Pten: a new guardian of the genome. Oncogene 27(41):5443–5453CrossRefPubMed

Song MS, Salmena L, Pandolfi PP (2012) The functions and regulation of the pten tumour suppressor. Nat Rev Mol Cell Biol 13(5):283–296PubMed

Goldbrunner M BKM120 Investigator's Brochure, Edition 1, 09-Sep-2008

10.

Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, Brachmann S et al (2012) Identification and characterization of nvp-bkm120, an orally available pan-class i pi3-kinase inhibitor. Mol Cancer Ther 11(2):317–328CrossRefPubMed

11.

Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, Demanse D, De Buck SS, Ru QC, Peters M, Goldbrunner M et al (2012) Phase i, dose-escalation study of bkm120, an oral pan-class i pi3k inhibitor, in patients with advanced solid tumors. J Clin Oncol 30(3):282–290CrossRefPubMed

12.

Vansteenkiste JF, Canon JL, De Braud F, Grossi F, De Pas T, Gray JE, Su WC, Felip E, Yoshioka H, Gridelli C, Dy GK et al (2015) Safety and efficacy of buparlisib (bkm120) in patients with pi3k pathway-activated non-small cell lung cancer (nsclc): results from the phase ii basalt-1 study. J Thorac Oncol 10(9):1319–1327

13.

Ando Y, Inada-Inoue M, Mitsuma A, Yoshino T, Ohtsu A, Suenaga N, Sato M, Kakizume T, Robson M, Quadt C, Doi T (2014) Phase i dose-escalation study of buparlisib (bkm120), an oral pan-class i pi3k inhibitor, in japanese patients with advanced solid tumors. Cancer Sci 105(3):347–353CrossRefPubMedPubMedCentral

14.

Saura C, Bendell J, Jerusalem G, Su S, Ru Q, De Buck S, Mills D, Ruquet S, Bosch A, Urruticoechea A, Beck JT et al (2014) Phase ib study of buparlisib plus trastuzumab in patients with her2-positive advanced or metastatic breast cancer that has progressed on trastuzumab-based therapy. Clin Cancer Res 20(7):1935–1945CrossRefPubMed

15.

Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, Cantley LC et al (2014) Stand up to cancer phase ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 32(12):1202–1209CrossRefPubMedPubMedCentral

16.

Ihle NT, Williams R, Chow S, Chew W, Berggren MI, Paine-Murrieta G, Minion DJ, Halter RJ, Wipf P, Abraham R, Kirkpatrick L et al (2004) Molecular pharmacology and antitumor activity of px-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther 3(7):763–772PubMed

17.

Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB (2002) Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 62(4):1087–1092PubMed

18.

Hyman DM, Snyder AE, Carvajal RD, Gerecitano JF, Voss MH, Ho AL, Konner J, Winkelmann JL, Stasi MA, Monson KR, Iasonos A et al (2015) Parallel phase ib studies of two schedules of buparlisib (bkm120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors. Cancer Chemother Pharmacol 75(4):747–755CrossRefPubMed

19.

Wee S, Wiederschain D, Maira SM, Loo A (2008) Miller C, deBeaumont R, Stegmeier F, Yao YM, Lengauer C: Pten-deficient cancers depend on pik3cb. Proc Natl Acad Sci U S A 105(35):13057–13062CrossRefPubMedPubMedCentral

20.

Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, Zhao JJ (2008) Essential roles of pi(3)k-p110beta in cell growth, metabolism and tumorigenesis. Nature 454(7205):776–779PubMedPubMedCentral

21.

Bassi C, Ho J, Srikumar T, Dowling RJ, Gorrini C, Miller SJ, Mak TW, Neel BG, Raught B, Stambolic V (2013) Nuclear pten controls DNA repair and sensitivity to genotoxic stress. Science (New York, NY) 341(6144):395–399CrossRef

22.

Kroenke K, Spitzer RL, Williams JB (2001) The phq-9: validity of a brief depression severity measure. J Gen Intern Med 16(9):606–613CrossRefPubMedPubMedCentral

23.

Spitzer RL, Kroenke K, Williams JB, Lowe B (2006) A brief measure for assessing generalized anxiety disorder: the gad-7. Arch Intern Med 166(10):1092–1097CrossRefPubMed

24.

Wagle N, Berger MF, Davis MJ, Blumenstiel B, Defelice M, Pochanard P, Ducar M, Van Hummelen P, Macconaill LE, Hahn WC, Meyerson M et al (2012) High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2(1):82–93CrossRefPubMed

25.

Vakiani E, Janakiraman M, Shen R, Sinha R, Zeng Z, Shia J, Cercek A, Kemeny N, D'Angelica M, Viale A, Heguy A et al (2012) Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol 30(24):2956–2962CrossRefPubMedPubMedCentral

26.

Janakiraman M, Vakiani E, Zeng Z, Pratilas CA, Taylor BS, Chitale D, Halilovic E, Wilson M, Huberman K, Ricarte Filho JC, Persaud Y et al (2010) Genomic and biological characterization of exon 4 kras mutations in human cancer. Cancer Res 70(14):5901–5911CrossRefPubMedPubMedCentral

27.

Reidy DL, Vakiani E, Fakih MG, Saif MW, Hecht JR, Goodman-Davis N, Hollywood E, Shia J, Schwartz J, Chandrawansa K, Dontabhaktuni A et al (2010) Randomized, phase ii study of the insulin-like growth factor-1 receptor inhibitor imc-a12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol 28(27):4240–4246CrossRefPubMedPubMedCentral

28.

Sakr RA, Barbashina V, Morrogh M, Chandarlapaty S, Andrade VP, Arroyo CD, Olvera N, King TA (2010) Protocol for pten expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma. Appl Immunohistochem Mol Morphol 18(4):371–374CrossRefPubMedPubMedCentral

29.

Wong KM, Capasso A, Eckhardt SG (2016) The changing landscape of phase i trials in oncology. Nat Rev Clin Oncol 13(2):106–117CrossRefPubMed

30.

Ivy SP, Siu LL, Garrett-Mayer E, Rubinstein L (2010) Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res 16(6):1726–1736CrossRefPubMedPubMedCentral

31.

Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN et al (2004) Pten activation contributes to tumor inhibition by trastuzumab, and loss of pten predicts trastuzumab resistance in patients. Cancer Cell 6(2):117–127CrossRefPubMed

32.

Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL et al (2007) A functional genetic approach identifies the pi3k pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12(4):395–402CrossRefPubMed

33.

Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M, Koujak S, Ferrando AA, Malmstrom P, Memeo L, Isola J et al (2007) Poor prognosis in carcinoma is associated with a gene expression signature of aberrant pten tumor suppressor pathway activity. Proc Natl Acad Sci U S A 104(18):7564–7569CrossRefPubMedPubMedCentral

34.

Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF et al (2008) An integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer. Cancer Res 68(15):6084–6091CrossRefPubMedPubMedCentral

35.

Razis E, Bobos M, Kotoula V, Eleftheraki AG, Kalofonos HP, Pavlakis K, Papakostas P, Aravantinos G, Rigakos G, Efstratiou I, Petraki K et al (2011) Evaluation of the association of pik3ca mutations and pten loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat 128(2):447–456CrossRefPubMed

36.

Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, Sahin AA, Hortobagyi GN, Yu D (2010) Pten, pik3ca, p-akt, and p-p70s6k status: association with trastuzumab response and survival in patients with her2-positive metastatic breast cancer. Am J Pathol 177(4):1647–1656CrossRefPubMedPubMedCentral

37.

Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, Narasanna A, Chakrabarty A, Hilsenbeck SG, Huang J, Rimawi M et al (2011) Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 29(2):166–173CrossRefPubMed

38.

Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, Xiong Y, Zhang S, Krop IE, Winer EP, Kindelberger DW et al (2011) Phase i/ii study of trastuzumab in combination with everolimus (rad001) in patients with her2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol 29(23):3126–3132CrossRefPubMedPubMedCentral

39.

Shen Y, Yang J, Xu Z, Gu DY, Chen JF (2012) Phosphatase and tensin homolog expression related to cetuximab effects in colorectal cancer patients: a meta-analysis. World J Gastroenterol 18(21):2712–2718CrossRefPubMedPubMedCentral

40.

Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestrari E et al (2009) Pten expression and kras mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27(16):2622–2629CrossRefPubMed

41.

Edgar KA, Wallin JJ, Berry M, Lee LB, Prior WW, Sampath D, Friedman LS, Belvin M (2010) Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors. Cancer Res 70(3):1164–1172CrossRefPubMed

42.

Ni J, Liu Q, Xie S, Carlson C, Von T, Vogel K, Riddle S, Benes C, Eck M, Roberts T, Gray N et al (2012) Functional characterization of an isoform-selective inhibitor of pi3k-p110beta as a potential anticancer agent. Cancer Discov 2(5):425–433CrossRefPubMedPubMedCentral

43.

Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L (2011) Pten restoration and pik3cb knockdown synergistically suppress glioblastoma growth in vitro and in xenografts. J Neuro-Oncol 104(1):155–167CrossRef

44.

Loibl S, de la Pena L, Nekljudova V, Zardavas D, Michiels S, Denkert C, Rezai M, Bermejo B, Lee S-C, Turri S, Urban P, Kümmel S, Lux M, Piccart M, von Minckwitz G, Baselga J, Loi S (2015) Phase II, randomized, parallel-cohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive, PIK3CA mutant and PIK3CA wild-type primary breast cancer – NeoPHOEBE. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia

45.

Alex A, Adjei, JB, Leighl NB, Felip Enriqueta, Cortinovis DL, Alt J, Schaefer ES, Thomas M, Chouaid C, Morabito A, Castro De J, Grossi F, Paz-Ares L, Pas De TM, Maier J, Chakravartty A, Chol M, Aimone P, Planchard D (2016) Safety and efficacy of buparlisib (bkm120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqnsclc): Results from the phase ib/ii basalt-2 and basalt-3 studies ASCO 2016 Annual meeting

46.

Denis, S SJF, Mesia R, Remenar E, Li S-H, Karpenko A, Dechaphunkul A, Keilholz U, Kiss LA, Lin JC, Nagarkar RV, Tamas L, Kim S-B, Erfán J, Turri S, Dey D, Chakravartty A, Aimone P, Massacesi C, Licitra LF (2016) Beril-1: A phase ii, placebo-controlled study of buparlisib (bkm120) plus paclitaxel in patients withplatinum-pretreated recurrent/metastatic head and neck squamous cell carcinoma (hnscc). ASCO 2016 Annual meeting

Titel: A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
verfasst von: Lillian M. Smyth
Kelsey R. Monson
Komal Jhaveri
Alexander Drilon
Bob T. Li
Wassim Abida
Gopa Iyer
John F. Gerecitano
Mrinal Gounder
James J. Harding
Martin H. Voss
Vicky Makker
Alan L. Ho
Pedram Razavi
Alexia Iasonos
Philip Bialer
Mario E. Lacouture
Jerrold B. Teitcher
Joseph P. Erinjeri
Nora Katabi
Matthew G. Fury
David M. Hyman
Publikationsdatum: 09.03.2017
Verlag: Springer US
Erschienen in: Investigational New Drugs / Ausgabe 6/2017
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-017-0445-0

Springer Medizin

A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel

Summary

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2017

Metformin as a repurposed therapy in advanced non-small cell lung cancer (NSCLC): results of a phase II trial

Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations

Urolithins impair cell proliferation, arrest the cell cycle and induce apoptosis in UMUC3 bladder cancer cells

Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer

Novel inhibitors of lysine (K)-specific Demethylase 4A with anticancer activity

Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie